Rockefeller Capital Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
Other funds holding OCUL
SR
Rockefeller Capital Management's OCUL Position: Q3 2026 in Review
Rockefeller Capital Management increased its Ocular Therapeutix (OCUL) stake by 153% in Q3 2026, buying an estimated $47.7K and bringing the position to 8,051 shares worth $61.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.
Rockefeller Capital Management first reported a position in OCUL in Q4 2025 and has held it in 4 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.
- Rockefeller Capital Management held 8,051 shares of Ocular Therapeutix worth $61.8K as of Q3 2026.
- Rockefeller Capital Management bought 4,870 Ocular Therapeutix shares in Q3 2026, an estimated $47.7K.
- Ocular Therapeutix made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3343 holding.
- Rockefeller Capital Management first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 4 quarters since.
- 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.